Abstract
This paper was developed in the Civil Systems Engineering Department at the Technical University of Berlin. The background is the spread of COVID-19 pandemic in Germany. Our current situation is a threat from the COVID-19 virus without vaccine and medication. Germany has increased its intensive capacities, intensified research in its analyzes and research projects and is currently testing the influence of various measures on the rate of expansion.
The goal now is to find a strategy that slows the spread so that medical capacities are not overloaded. The approach is to alternate between quarantine and normal episodes and the result is an oscillation in the number of cases between two limits.
The mathematical model is an SRI model that can be used to calculate the development of the case numbers. All uncertain parameters are varied at significant intervals. Influence parameters and control parameters were defined. By adjusting the length of the episode to match the speed of spread of the virus, the gap can be bridged until a vaccine has been developed or sufficient immunity is available in the population. By observing the capacity limits in connection with the number of cases, the need for a new quarantine episode and the possibility of initiating a normal episode can be predetermined. This does not exceed the capacity limit.
In quarantine, contagion within households is limited by the size of the household; only system-critical professions continue to work in public. All others must remain in the homeschooling / home office. In the normal episode, everyone can work, go to school, have social contacts. A solution could be found in all parameter combinations. The ratio of the normal episode duration / quarantine episode lies between 0.3 and 0.95 in the examination area.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There were no payments or services from a third party.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available on request. carolinknoch{at}yahoo.com
